Literature DB >> 3290187

Antibiotic therapy of nonenterococcal streptococcal and staphylococcal endocarditis: current regimens and some future considerations.

A W Karchmer1.   

Abstract

Regimens for endocarditis caused by these bacteria are generally based on high dosage of a beta-lactam antibiotic, penicillin in the case of streptococci and a penicillinase-resistant penicillin for Staphylococcus aureus, with vancomycin substituted for beta-lactam resistant staphylococci, including coagulase-negative staphylococci. The addition of other antimicrobial agents, such as aminoglycosides (or, in the case of staphylococci, sodium fusidate or rifampicin) may increase bactericidal efficiency, or allow shorter courses, but problems of toxicity or emergence of resistance may occur. Optimal regimens are discussed, and newer agents of possible usefulness are reviewed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3290187     DOI: 10.1093/jac/21.suppl_c.91

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Staphylococcus lugdunensis.

Authors:  K F Barker; J C O'Driscoll; A Bhargava
Journal:  J Clin Pathol       Date:  1991-10       Impact factor: 3.411

Review 2.  Rational approaches to the treatment of culture-negative infective endocarditis.

Authors:  I R Gray
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

3.  In vitro activity of trospectomycin (U-63366F), a novel spectinomycin analog, against gram-positive isolates from cancer patients.

Authors:  K Rolston; D H Ho; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.